Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2009 |
| End Date: | March 2012 |
A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF
This study is being conducted to test study drug AZD1480 to see how it may work to treat
myeloproliferative diseases. The main purpose of this study is to determine the safety and
tolerability of AZD1480. This is the first time the drug has been given to humans and is
classed as a first time in man study. Its main purpose is to establish a safe dosage of the
drug and provide additional information on any potential side effects this drug may cause.
The study will also assess the blood levels and action of AZD1480 in the body over a period
of time and will indicate whether the drug has a therapeutic effect on myeloproliferative
diseases.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials